Biotech Values

[DewDiligence]

I could also see Teva suing the FDA in that situation, as SNY did re Lovenox.

Unlikely, IMO. In addition to the point raised by OB in #msg-63698660, Teva’s suing the FDA would be inconsistent with Teva’s desire to settle the Copaxone litigation with NVS/MNTA and thereby ensure a little more time with market exclusivity. Teva’s situation with Copaxone is fundamentally different from SNY’s situation with Lovenox, where a settlement with NVS/MNTA was no longer possible.